加载中
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
前收盘价
US$1.78
−US$0.11 · -5.82%
盘后
US$1.78
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
日内区间
当前US$1.78
52周区间
当前US$1.78
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
46
合理估值
情绪
45
多空交织
风险
63
高风险
动量
79
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
日内区间
当前US$1.78
52周区间
当前US$1.78
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5万 USD | 1.4万 USD | 15.5万 USD | 37.4万 USD | 18.1万 USD |
| 毛利 | 5万 USD | 1.4万 USD | 15.5万 USD | 37.4万 USD | 18.1万 USD |
| 研究与开发 | 2065.9万 USD | 3316.6万 USD | 2027.3万 USD | 1706.7万 USD | 2054.3万 USD |
| 销售、一般及管理费用 | 1026万 USD | 948.3万 USD | 962.3万 USD | 925.8万 USD | 879.1万 USD |
| 营业费用 | 3091.9万 USD | 4264.9万 USD | 2989.6万 USD | 2632.5万 USD | 2933.4万 USD |
| 利息收入 | 85万 USD | — | — | — | — |
| 折旧和摊销 | 8.4万 USD | 55.3万 USD | 2974.1万 USD | 2595.1万 USD | 2915.3万 USD |
| 营业利润 | −3086.9万 USD | −4263.5万 USD | −2974.1万 USD | −2595.1万 USD | −2915.3万 USD |
| 净利润 | −4593.3万 USD | −4208.2万 USD | −3000.8万 USD | −2729.9万 USD | −3034万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI112.76万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF45.08万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC14.61万0.01%13.17亿 USD0.60%US$181.66-0.73%
U.S. Micro Cap Portfolio ETFDFMC1.09万0.00%75.58亿 USD0.43%US$57.70-0.20%
Dimensional - US Small Cap ETFDFAS8064.630.00%338.69亿 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
